Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 274,619 shares at $0.72 ($198K) on 2026-04-30, disclosed to the SEC on 2026-05-04.
Scheduled sale ($198k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.72 | 168,262 | $121K | 61.1% |
| 2 | $0.73 | 58,394 | $43K | 21.5% |
| 3 | $0.72 | 47,963 | $35K | 17.4% |
| Total | $0.72 avg | 274,619 | $198K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-06-03 | $64K | — | Filing → |